A Trial to Study of the Effects of Eletriptan 40mg on Mild vs Moderate to Severe Pain Intensity of Migraine

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of early intervention (dosing within 2 hours of onset of the migraine attack) with eletriptan 40mg on mild versus moderate to severe pain intensity of migraine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Eletriptan

Criteria

Inclusion Criteria:

• Diagnosis of migraine with or without aura according to the recent IHS criteria.

• Migraine headaches must have been present for more than one year.

• History in the last 3 months of 1 to 4 acute attacks of migraine headache per month.

Exclusion Criteria:

• Subjects with current or past history of coronary artery disease.

• Pregnant or breastfeeding women.

• Subjects who have chronic daily headaches.